Company Profile - Pharming Group NV

Introduction

Pharming Group NV (Pharming) develops precision medicines and innovative protein replacement therapies for the treatment of rare diseases and unmet medical needs. The company’s marketed product includes, Ruconest (conestat alfa), a recombinant human C1 inhibitor is used for the treatment of acute hereditary angioedema (HAE) and has been approved in the US, the UK, Europe, Israel, and South Korea. Its product pipeline consists of leniolisib for treatment of activated phosphoinositide 3-kinase delta syndrome (APDS); α-Glucosidase for the treatment of Pompe disease. The company markets its products through own sales force and network of distributors and partners. Pharming is headquartered in Leiden, the Netherlands.